HIVE vs XRPN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 30, 2026

HIVE

63.5
AI Score
VS
HIVE Wins

XRPN

58.3
AI Score

Investment Advisor Scores

HIVE

64score
Recommendation
HOLD

XRPN

58score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric HIVE XRPN Winner
Forward P/E 62.8931 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 73.5% 0.0% HIVE
Earnings Growth -99.9% 4.6% XRPN
Tradestie Score 63.5/100 58.3/100 HIVE
Profit Margin -98.5% 0.0% XRPN
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

HIVE 1M: -26.2% · 3M: -32.2% XRPN 1M: -43.7% · 3M: -11.5%

Current Technical Phase

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -12.6%), weak momentum, RSI 36

RSI (14): 35.9 · Price: $1.75

XRPN

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 38

RSI (14): 37.7 · Price: $9.28

Fundamentals Snapshot

Metric HIVE XRPN
Market Cap — —
Forward P/E -3.4 0.0
Trailing P/E — 113.7
Revenue (TTM) — —
Revenue Growth 0.7% 0.0%
Gross Margin 0.4% —
Operating Margin -0.6% 0.0%
EPS -1.53 0.07
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.